Diagnostics
Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms Excerpt from the Press Release: WEXFORD, Pa., May 17, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…
Read More
Excerpt from the Press Release: The Ontario Brain Institute (OBI) has released a new set of clinical imaging modalities from a Province of Ontario Neurodevelopmental Network (POND) study for cohort of over 600 children and youth, some diagnosed with various neurodevelopmental disorders and others typically developing.This cleaned, standardized, and curated dataset is available for download on Brain-CODE, OBI’s neuroinformatics and analytics platform.…
Read More
News Summary: Waters opens its newest innovation and research laboratory at University of Delaware (UD) Science, Technology and Advanced Research (STAR) campus Immerse™ Delaware brings together students, faculty, and Waters scientists with industry research partners to identify and address significant challenges facing the biopharmaceutical industry Lab opening milestone is part of multi-year Waters-UD research partnership…
Read More
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Robust phase 3 clinical program includes two complementary trials (ASTER and MAGNOLIA) that will enroll ~2700 patients to study abelacimab in patients with Cancer Associated Thrombosis (CAT) The ASTER study will compare abelacimab against the most widely…
Read More
Peer-reviewed results from the two-level multi-center FDA Investigational Device Exemption study reiterate disc’s superiority to ACDF Excerpt from the Press Release: SAN DIEGO, April 21, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify® Cervical Disc (Simplify Disc) two-level U.S. Food…
Read More Excerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel…
Read More
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer Excerpt from the Press Release: CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies…
Read More
In a phase 2a study, CHOP researchers showed exendin-(9-39) leads to blood sugar control in children with HI, which could improve care for a rare condition with few treatments Excerpt from the Press Release: PHILADELPHIA, April 13, 2022 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have shown that a targeted treatment they developed is effective at controlling…
Read More
ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to ~9 months from historical data with KEYTRUDA® alone Median overall survival of 33.7…
Read More
If authorized by the FDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for COVID-19 (SARS-CoV-2) in as little as 18 minutes Excerpt from the Press Release: CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ — Proof Diagnostics, Inc., an innovative healthcare technology company delivering innovative solutions in molecular diagnostics, today announced the submission…
Read More